# Fat-to-Muscle Ratio: Surgery Versus Drugs

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-31

Canonical page: https://glpwatchdog.org/research/fat-to-muscle-ratio-surgery-vs-drugs

> The lean-to-fat ratio improved in both groups at 6, 12 and 24 months. Everyone loses lean tissue when losing weight. The question is the mix, and both interventions improved it.

## Key points

- Lean-to-fat ratio improved in both groups: surgery 1.8→2.1→2.0, GLP-1 1.4→1.5→1.5.
- Fat fell faster than lean, so the body ends up proportionally more muscular, not wasted.
- Single-center cohort; surgical aftercare usually includes protein and supplement guidance, which may itself help preserve lean mass.
- Men preserved fat-free mass better, while women lose a larger percentage of total weight on these drugs.

Most arguments about muscle loss count the wrong thing, the amount of lean tissue lost. What matters is the *mix*: how much lean comes off relative to fat. A cohort study measured exactly that after bariatric surgery and after semaglutide or tirzepatide, and the ratio improved in **both** groups at every time point.[1]

## The numbers

*Fat-free mass to fat mass ratio. Higher is a more favorable body composition.*

| Time point | Bariatric surgery | GLP-1 receptor agonists |
| --- | --- | --- |
| 6 months | 1.8 | 1.4 |
| 12 months | 2.1 | 1.5 |
| 24 months | 2.0 | 1.5 |

Both groups lost substantial fat mass and moderate fat-free mass, and both improved the ratio between them. Surgery maintained a higher ratio throughout.[1]

> **The improving ratio is the finding people miss.** Losing lean tissue while losing weight sounds like damage, and in isolation it looks like it. But if fat falls faster than lean, the body you end up with is proportionally *more* muscular than the one you started with, which is the opposite of wasting. Both interventions did that. It also means a lean percentage can rise while lean tissue falls, as [one compounded semaglutide study](https://glpwatchdog.org/research/a-proportion-that-rises-by-itself) shows.

## Why the comparison between columns is the weak part

This is a single-center cohort study, not a randomized comparison, and people who have bariatric surgery differ enormously from people prescribed a GLP-1. They differ in starting weight, in how long they have been trying, in what else has failed, and in the post-operative nutrition and follow-up programs that surgery carries with it.

Surgical patients also get nutritional follow-up as part of aftercare: the US perioperative guideline calls for a team approach “with special attention to nutritional and metabolic issues.”[3] That kind of support may help preserve lean mass. Some of that column difference may be the aftercare rather than the procedure. We cover the broader comparison in [surgery versus GLP-1 drugs](https://glpwatchdog.org/research/surgery-versus-glp1-drugs), including a widely quoted [28% against 10% weight figure that rests on 257 people](https://glpwatchdog.org/research/the-weight-comparison-used-257-people) in the drug arm.

> Surgical aftercare includes nutritional follow-up,[3] so part of the gap between the columns may be the aftercare, not the operation.

## The sex difference runs the other way

One stratified result points the opposite way from a better-known finding. **Men preserved fat-free mass better than women**, especially after GLP-1 treatment.[1]

Women, meanwhile, lose a larger *percentage* of body weight on these drugs: 10.9% against 6.8% across the six trials that reported results by sex in a 64-trial review,[2] covered in [who loses more weight](https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1). The two findings do not contradict each other. One is about how much total weight comes off, the other about what that weight is made of.

Either way, the advice is the same: resistance training, which has randomized support for changing the mix, and adequate protein. Our [lean mass article](https://glpwatchdog.org/research/lean-mass-drug-versus-dieting) has the figures, and [protein targets](https://glpwatchdog.org/research/protein-targets-and-the-lab-panel) covers how much to eat.

## Frequently asked questions

### Do GLP-1 drugs worsen body composition?

No. In this cohort the fat-free mass to fat mass ratio improved on these drugs at 6, 12 and 24 months. Lean tissue was lost, but fat was lost faster, leaving a proportionally more muscular body than at the start.

### Is surgery better for body composition?

Surgical patients maintained a higher ratio throughout in this study, but it is a single-center cohort rather than a randomized comparison, and surgery usually comes with structured protein and supplement aftercare, which may itself help preserve lean mass. The gap between the two groups is the weakest part of the finding.

### Why is the ratio a better measure than lean mass alone?

Because everyone loses some lean tissue when they lose weight, so the absolute figure always looks alarming. The ratio tells you whether fat came off faster than lean, which is what determines the body you end up with.

### Do men and women differ?

In this study men preserved fat-free mass better, especially after GLP-1 treatment. That sits alongside a separate finding that women lose a larger percentage of total body weight. They answer different questions: how much comes off, and what it is made of.

### What changes the mix in your favor?

Resistance training with adequate protein. Resistance training has randomized support for shifting the proportion of weight lost as lean mass, and it applies whichever route the weight loss came from.

## References

1. Wang Z, Wang L, Zhang X, et al. Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists. JAMA Network Open. 2026. PMID: 41511769. https://pubmed.ncbi.nlm.nih.gov/41511769/
2. Alexander GC, Xiao X, Dilek S, et al. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis. JAMA Internal Medicine. 2026. PMID: 41770554. https://pubmed.ncbi.nlm.nih.gov/41770554/
3. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020. PMID: 31917200. DOI: 10.1016/j.soard.2019.10.025. https://pubmed.ncbi.nlm.nih.gov/31917200/

---

Cite as: GLP Watchdog, Nora Bissett, "Fat-to-Muscle Ratio: Surgery Versus Drugs", published 2026-08-19, updated 2026-10-31. https://glpwatchdog.org/research/fat-to-muscle-ratio-surgery-vs-drugs

Canonical HTML page: https://glpwatchdog.org/research/fat-to-muscle-ratio-surgery-vs-drugs

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
